Erratum to: Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids (Metabolic Brain Disease, (2015), 30, 5, (1257-1267), 10.1007/s11011-015-9705-x);Activities of genes controlling sphingolipid metabolism in human fibroblasts treated with flavonoids

Metabolic Brain Disease

Volumn 30, Issue 5, 2015, Pages 1257-1267

  Moskot, Marta ^a   Jakóbkiewicz Banecka, Joanna ^a   Smolińska, Elwira ^a   Banecki, Bogdan ^b   Węgrzyn, Grzegorz ^a   Gabig Cimińska, Magdalena ^a  

^a UNIVERSITY OF GDA SK   (Poland)

^b University of Gdańsk ^*  (Poland)

Author keywords

Flavonoid; Gene expression regulation; Lysosomal storage disease; Sphingolipid metabolism

Indexed keywords

DAIDZEIN; DNA; FLAVONOID; GENISTEIN; GLYCOSPHINGOLIPID; KAEMPFEROL; MESSENGER RNA; SPHINGOLIPID;

ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE ACTIVITY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC CODE; HUMAN; HUMAN CELL; LIPOGENESIS; LYSOSOME STORAGE DISEASE; METABOLIC ENCEPHALOPATHY; METABOLIC REGULATION; MICROARRAY ANALYSIS; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SPHINGOLIPID METABOLISM; UPREGULATION; CELL CULTURE; DRUG EFFECTS; FIBROBLAST; GENETICS; LIPID METABOLISM; METABOLISM; PHYSIOLOGY; PROCEDURES;

CELLS, CULTURED; FIBROBLASTS; FLAVONOIDS; GENE EXPRESSION PROFILING; HUMANS; LIPID METABOLISM; REAL-TIME POLYMERASE CHAIN REACTION; SPHINGOLIPIDS;

EID: 84941189276     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-017-9974-7     Document Type: Erratum

References (37)

1. Arfi A, Richard M, Gandolphe C, Scherman D (2010) Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 33:61–67
2. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, Mcdonald M, Finkel R, Packman S, Bichet DG, Warnock DG, Desnick RJ (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
3. Boukhris A, Schule R, Loureiro JL, Lourenco CM, Mundwiller E, Gonzalez MA, Charles P, Gauthier J, Rekik I, Acosta Lebrigio RF, Gaussen M, Speziani F, Ferbert A, Feki I, Caballero-Oteyza A, Dionne-Laporte A, Amri M, Noreau A, Forlani S, Cruz VT, Mochel F, Coutinho P, Dion P, Mhiri C, Schols L, Pouget J, Darios F, Rouleau GA, Marques Jr W, Brice A, Durr A, Zuchner S, Stevanin G (2013) Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet 93:118–123
4. Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57:283–296
5. Conzelmann E, Sandhoff K (1983) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6:58–71
6. Ferlinz K, Hurwitz R, Weiler M, Suzuki K, Sandhoff K, Vanier MT (1995) Molecular analysis of the acid sphingomyelinase deficiency in a family with an intermediate form of Niemann-Pick disease. Am J Hum Genet 56:1343–1349
7. Gieselmann V (2005) What can cell biology tell us about heterogeneity in lysosomal storage diseases? Acta Paediatr Suppl 94:80–86 discussion 79
8. Gillard BK, Clement RG, Marcus DM (1998) Variations among cell lines in the synthesis of sphingolipids in de novo and recycling pathways. Glycobiology 8:885–890
9. Hollak CE, De Fost M, Van Dussen L, Vom Dahl S, Aerts JM (2009) Enzyme therapy for the treatment of type 1 gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother 10:2641–2652
10. Jakobkiewicz-Banecka J, Piotrowska E, Narajczyk M, Baranska S, Wegrzyn G (2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J Biomed Sci 16:26
11. Jeyakumar M, Williams I, Smith D, Cox TM, Platt FM (2009) Critical role of iron in the pathogenesis of the murine gangliosidoses. Neurobiol Dis 34:406–416
12. Kanehisa M, Goto S, Hattori M, Aoki-Kinoshita KF, Itoh M, Kawashima S, Katayama T, Araki M, Hirakawa M (2006) From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res 34:D354–D357
13. Kloska A, Jakobkiewicz-Banecka J, Narajczyk M, Banecka-Majkutewicz Z, Wegrzyn G (2011) Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab Brain Dis 26:1–8
14. Kolter T, Sandhoff K (2006) Sphingolipid metabolism diseases. Biochim Biophys Acta 1758:2057–2079
15. Leinekugel P, Michel S, Conzelmann E, Sandhoff K (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88:513–523
16. Lim-Melia ER, Kronn DF (2009) Current enzyme replacement therapy for the treatment of lysosomal storage diseases. Pediatr Ann 38:448–455
17. Moskot M, Montefusco S, Jakobkiewicz-Banecka J, Mozolewski P, Wegrzyn A, Di Bernardo D, Wegrzyn G, Medina DL, Ballabio A, Gabig-Ciminska M (2014) The phytoestrogen genistein modulates lysosomal metabolism and transcription factor EB (TFEB) activation. J Biol Chem 289:17054–17069
18. Moskot M, Jakobkiewicz-Banecka J, Kloska A, Smolinska E, Mozolewski P, Malinowska M, Rychlowski M, Banecki B, Wegrzyn G, Gabig-Ciminska M (2015) Modulation of expression of genes involved in glycosaminoglycan metabolism and lysosome biogenesis by flavonoids. Sci Rep 5:9378
19. Pastores GM (2010) Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs 24:41–47
20. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27:1215–1227
21. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, Wegrzyn A, Wegrzyn G (2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur J Hum Genet 14:846–852
22. Platt FM, Boland B, Van Der Spoel AC (2012) The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. J Cell Biol 199:723–734
23. Rohrbach M, Clarke JT (2007) Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs 67:2697–2716
24. Rosenbaum AI, Maxfield FR (2011) Niemann-Pick type C disease: molecular mechanisms and potential therapeutic approaches. J Neurochem 116:789–795
25. Sandhoff K (2013) Metabolic and cellular bases of sphingolipidoses. Biochem Soc Trans 41:1562–1568
26. Sardiello M, Palmieri M, Di Ronza A, Medina DL, Valenza M, Gennarino VA, Di Malta C, Donaudy F, Embrione V, Polishchuk RS, Banfi S, Parenti G, Cattaneo E, Ballabio A (2009) A gene network regulating lysosomal biogenesis and function. Science 325:473–477
27. Schnaar RL (2005) In: Fukuda M, Rutishauser U, Schnaar RL, Yamaguchi Y (eds) Neuroglycobiology. Oxford University Press, Oxford, pp. 95–113
28. Schnaar RL (2009) Essentials of glycobiology. Cold Spring Harbour Laboratory Press, Cold Spring Harbour
29. Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. Trends Neurosci 34:401–410
30. Simpson MA, Cross H, Proukakis C, Priestman DA, Neville DC, Reinkensmeier G, Wang H, Wiznitzer M, Gurtz K, Verganelaki A, Pryde A, Patton MA, Dwek RA, Butters TD, Platt FM, Crosby AH (2004) Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat Genet 36:1225–1229
31. Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, Togawa T, Chiba Y, Jigami Y, Ohno K, Fukushige T, Kanekura T, Itoh K, Ohashi T, Sakuraba H (2009) Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am J Hum Genet 85:569–580
32. Takamura A, Higaki K, Kajimaki K, Otsuka S, Ninomiya H, Matsuda J, Ohno K, Suzuki Y, Nanba E (2008) Enhanced autophagy and mitochondrial aberrations in murine G(M1)-gangliosidosis. Biochem Biophys Res Commun 367:616–622
33. Tan MA, Fuller M, Zabidi-Hussin ZA, Hopwood JJ, Meikle PJ (2010) Biochemical profiling to predict disease severity in metachromatic leukodystrophy. Mol Genet Metab 99:142–148
34. Tettamanti G, Bassi R, Viani P, Riboni L (2003) Salvage pathways in glycosphingolipid metabolism. Biochimie 85:423–437
35. Tomatsu S, Almeciga-Diaz CJ, Montano AM, Yabe H, Tanaka A, Dung VC, Giugliani R, Kubaski F, Mason RW, Yasuda E, Sawamoto K, Mackenzie W, Suzuki Y, Orii KE, Barrera LA, Sly WS, Orii T (2014) Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab
36. Tsai TH (2005) Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J Chromatogr A 1073:317–322
37. Yamashita T, Wada R, Sasaki T, Deng C, Bierfreund U, Sandhoff K, Proia RL (1999) A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 96:9142–9147